Company intelligence / Profile preview

Digostics

Didcot, Oxfordshire, United Kingdom

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Digostics has developed and commercialized GTT@home, the world’s first home-based oral glucose tolerance test (OGTT) platform, used for diagnosing diabetes types and gestational diabetes; adopted by NHS trusts for gestational diabetes, piloted for Type 1 and 2 diabetes and cystic fibrosis-related diabetes, and engaged in research with major institutions[6].

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Metabolite Diagnostics

Partnerships

NHS Supply Chain (UK)University of OxfordYale Medical School (screening study site)Medical Research Council (UK) pilot

Beyond the preview

Go deeper on Digostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Digostics.

Explore the full profile